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Abstract
Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa
study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses,
safety, pharmacokinetics, and pharmacodynamic activity in children with relapsed/refractory
acute leukemia. The trial suffered from poor recruitment and terminated early, therefore fail-
ing to identify its primary endpoints. AT9283 caused tolerable toxicity, but failed to show clini-
cal responses. Future trials should be based on robust preclinical data that provide an indication
of which patients may benefit from the experimental agent, and recruitment should be improved
through international collaborations andearly combinationwith established treatment strategies.
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1 INTRODUCTION
Leukemia is the most commonmalignancy in childhood. Despite treat-
ment advances, the outcome of relapsed leukemia remains poor, with
Abbreviations: ABL, Abelson tyrosine kinase; AE, adverse event; ALL, acute lymphoblastic
leukemia; AML, acutemyeloid leukemia; AUC0-t, area under the plasma concentration time
curve; Cmax, maximum concentration; CDD, Centre for Drug Development; CNS, central
nervous system; CR-UK, Cancer Research UK; DLT, dose limiting toxicity; FLT3, FMS-like
tyrosine kinase 3; JAK, Janus kinase;MTD, maximum tolerated dose; PD, pharmacodynamic;
pHH3, phosphohistone H3; PK, pharmacokinetic; SAE, serious adverse event
5-year disease-free survival rates for relapsed acute lymphoblastic
leukemia (ALL) of 16%–39%,1 and relapsed acute myeloid leukemia
(AML) of 16%–34%.2 New treatment strategies are needed to improve
survival and reduce the toxicity of conventional chemotherapy.
Aurora kinases are a family of serine/threonine kinases involved in
mitosis and meiosis. The Aurora kinases are overexpressed in many
cancers, including leukemias,3 and overexpression has been linked to
genetic instability.
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AT9283 is a multikinase inhibitor affecting not only Aurora A and
B, but also FMS-like tyrosine kinase 3 (FLT3), the Janus kinase (JAK)
family, and Abelson tyrosine kinase (ABL).4 All of these are activated
in ALL and AML; FLT3 is commonly activated by mutation and ABL
by chromosomal translocations.5–9 A plethora of early phase clinical
trials are evaluating small molecule inhibitors against these kinases
(reviewed in10,11). Preclinical datahave shownthat inhibitionofAurora
A, B and FLT3 kinase by compound 27e led to growth inhibition in an
FLT3-ITD-positive AML xenograft.12 AT9283 has shown in vitro activ-
ity in cell linemodels formyeloproliferative disorderswith gain of func-
tion mutations in JAK213 and in adult phase I/II trials for solid tumors
andhematologicalmalignancies.14,15 In adultAML, approximately33%
of patients experienced a reduction in bone marrow blasts.15 The
first-in-child phase I trial with AT9283 in solid tumors leads to a par-
tial response in one patient (diagnosis: central nervous system [CNS]-
Primitiveneuroectodermal tumour (PNET)) anddisease stabilization in
38% of patients, with manageable hematological toxicity.16 The cur-
rent study is a first-in-child trial of AT9283 for relapsed/refractory
leukemia. The aims of the study were to identify the dose for explo-
ration of AT9283 in a phase II trial (primary objective), to evaluate
safety and tolerability of AT9283 by identifying dose-limiting toxicities
(DLTs), and to document preliminary activity and investigate its phar-
macokinetic (PK) profile (secondary objectives). Tertiary objectives
were to assess target inhibition by AT9283with a validated biomarker
assay17 and identify potential predictive biomarkers.
2 RESULTS
2.1 Study design, eligibility, and dose
escalation/drug schedule
Details regarding study design, eligibility criteria, definition of adverse
events (AEs)/DLTs, and information on dose escalation, drug sched-
ule, and assessments are summarized in Supplementary Appendix S1.
Written and signed informed consent was obtained from all par-
ents/guardians. The trial was sponsored by Cancer Research UK (CR-
UK) Centre for Drug Development (CDD) (study number CR0708-
12, EudraCT number 2009-016952-36, ClinicalTrials.gov identifier:
NCT01431664), and was conducted in accordance with the princi-
ples of Good Clinical Practice and CR-UK CDD’s Standard Operating
Procedures.
3 METHODS
PK analysis was identical to that described previously.16
Theplasma inhibitory activity assaywasused tomeasure ex vivo tar-
get kinase inhibition and had been validated for inhibition of Aurora,
ABL, and FLT3 kinase.17
Immunohistochemistry was used on surrogate tissue (skin punch
biopsies) to assess in vivo target kinase inhibition of Aurora kinase
(change in phosphohistone H3 [pHH3] levels), and changes in p53
(accumulation/stabilization) and Ki67/proliferating cell nuclear anti-
gen levels as biomarkers of antiproliferative responses.16
Other pharmacodynamic (PD) measurements included in vivo inhi-
bition of JAK-signal transducer and activator of transcription signal-
ing by flow cytometry, genetic screen for mutations in JAK1, 2, 3 and
FLT3, and copy number abnormalities of IKZF1 and PAX5 byMultiplex
Ligation-dependent Probe Amplification. For details, see Supplemen-
tary Appendix S1.
3.1 Patient characteristics
Ten patients underwent screening, seven of whom were eligible for
inclusion into the trial. Recruitment started in September 2011 and
the first patient was treated in April 2012. Of the seven patients,
five (71%) were male and two (29%) were female, with a median age
of 3 years (range, 1–18 years). Four patients were diagnosed with
relapsed/refractory AML and three patients had relapsed ALL.
Three dose levels of AT9283 were explored: three patients each at
9 and 14.5 mg/m2/day, and a further patient at 23 mg/m2/day. Each
patient receivedone cycle of treatment. All patientswithdrew fromthe
trial due to disease progression during or at the end of cycle 1. The trial
closed prematurely in July 2014 due to poor patient recruitment.
3.2 Toxicities
All patientswere evaluated for safety. A total of 97AEswere reported,
ofwhich29were considered tobe related (possible, probable, or highly
probable) to the administration of AT9283 (Supplementary Table S1).
Five patients experienced a total of 17 serious adverse events (SAEs),
of which 13were considered to be at least possibly related to AT9283.
None of the SAEs observedwere categorized as aDLT (Supplementary
Table S2). There was one patient death during the trial due to disease
progression, 22 days after the last administration of AT9283. Nomaxi-
mum tolerated dose (MTD) could be determined in this study.
3.3 Early response signals
None of the patients achieved a complete remission (<5% blasts in
bone marrow), a complete remission with incomplete bone marrow
recovery, or a partial remission (<25% blasts in bonemarrow).
3.4 Pharmacokinetics and pharmacodynamic assays
The PK parameters Cmax, AUC, half-life, and clearance values were
broadly comparable to the results reported from the pediatric solid
tumor study.16 Details of results regarding pharmacokinetics and
PD assays are presented in Figures 1 and 2 (and Supplementary
Appendix S1: Results; Supplementary Table S3 and Figure S1).
4 DISCUSSION
The current trial represents a first-in-child study of AT9283 in hema-
tological malignancies and highlights major challenges encountered
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F IGURE 1 Plot of AT9283 AUC (A) and Cmax (B) versus dose level
in the leukemic patient population of the study. Despite a high inter-
subject variability at both dose levels studied in three patients, there
was a general trend towards increasedCmax and increased exposure to
AT9283 (AUC) with increasing dose levels based on body surface area
when conducting early phase trials in patients with relapsed leukemia.
Despite being open for almost 3 years, the trial closed prematurely and
the primary endpoint of identifying a dose for phase II exploration was
not achieved. AT9283 was well tolerated at the dose levels explored,
without any DLTs, but with expected, mainly hematological toxicity.
The relatively low starting dose of 9mg/m2/day in comparisonwith the
adult leukemia MTD might have contributed towards the fact that no
evidence for clinical efficacy was observed.
Apart from the trial being open at only four sites, the important
reasons for the slow accrual were the rarity of eligible patients (e.g.,
patients with second/higher relapse are rare, CNS disease as exclu-
sion criteria) and competing studies towards the end of the recruit-
ment period (i.e., volasertib, moxetumomab, chimeric antigen recep-
tor (CAR) T cells, dacogen/cytarabine). Furthermore, the slow accrual
demonstrated the challenges in conducting early phase studies when
eligible patients per se are rare and where no preselection regarding
pathway activation/underlying mutations is undertaken. In our case,
selection for patients with leukemias carrying JAK, ABL, or FLT3muta-
tions might have increased the chance of observing clinical responses,
which could have translated into better recruitment.
In summary, the trial showed that AT9283has tolerable toxicity and
confirmed previous PK data, but it lacked any evidence of efficacy for
the doses explored. Our results, taken together with the experience
of AT9283 in adult leukemia,15 provide no evidence for AT9283 as
F IGURE 2 Plot of plasma inhibitory activity for all patients (A). Phos-
phorylated histoneH3 rawdensitometry data normalized to the corre-
sponding Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) sig-
nals on the total blot, expressed as a percentage of the screening sam-
ple (set at 100%), with subsequentmeasurements at 48 and 96 h. Six of
the seven patients (86%) had a decrease in pHH3 48 hours after the
start of AT9283 infusion, with inhibition of phosphorylation ranging
from 23% to 87%. p < 0.05 in one-way ANOVA with a multiple com-
parison test. (B) The relationship between AT9283 concentration and
inhibition of pHH3 phosphorylation at the 48 h time point
an active single agent in leukemia, and leave only few indications like
megakaryoblastic leukemia,18 in which future studies might be useful.
In general, novel agents like AT9283 should be added to established
standard chemotherapy platforms or to upfront single-agent window
studies, followed by other treatment elements, as single agents are
unlikely to be theway forward in thesemultiply relapsed patients. Fur-
thermore, successful completion of early phase trials in rare patient
populations is difficult in the national setting and such trials are better
conductedwithin international consortia, in order tomaximize patient
recruitment.
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